High expression of YTHDF2 in BC is associated with increased resistance to chemotherapeutic drugs such as fluorouracil, gemcitabine, and mitomycin C. YTHDF2 degrades DDX58 mRNA, which encodes RIG-I, thereby inhibiting the RIG-I signaling pathway and reducing apoptosis sensitivity. Here, RIGI is linked to breast cancer.